Plain Language Summary {#Sec1}
======================

Rheumatoid arthritis is a chronic, long-term disease. Medication is often required to control symptoms including pain and swollen joints. Many patients take a class of treatment called disease-modifying antirheumatic drugs (DMARDs). There are different types of DMARD, synthetic and biologic. Current treatment guidelines recommend combining drugs such as methotrexate (a [c]{.ul}onventional [s]{.ul}ynthetic DMARD) with other drugs such as etanercept (a [b]{.ul}iologic DMARD) or tofacitinib (a [t]{.ul}argeted [s]{.ul}ynthetic DMARD). As many as one-third of patients with rheumatoid arthritis are treated with bDMARDs or tsDMARDs alone. This type of treatment is called monotherapy. The aim of this review was to investigate which b/tsDMARDs are best used as monotherapy in the treatment of rheumatoid arthritis. Forty-four monotherapy studies of nine different DMARDs were identified in a literature search.

These b/tsDMARDs were shown to be effective treatments, even in patients who were intolerant of or had never used csDMARDs. However, better treatment outcomes were usually achieved with combination therapy. This was observed for all b/tsDMARDs assessed. Further studies are needed to show which treatments will be effective as monotherapy when used early in treating rheumatoid arthritis.

Introduction {#Sec2}
============

Effective treatment of rheumatoid arthritis (RA) requires the use of disease-modifying anti-rheumatic drugs (DMARDs). Traditional synthetic compounds such as methotrexate (MTX), sulfasalazine, and leflunomide are classified as conventional synthetic DMARDs (csDMARDs). Other synthetic compounds such as the Janus kinase (JAK) inhibitors tofacitinib (TOFA) and baricitinib (BARI), specifically developed to target the JAKs, are classified as targeted synthetic DMARDS (tsDMARDs). Biologic DMARDS (bDMARDs) are recombinant biologic molecules that recognize cell surface receptors or extracellular molecules with high specificity \[[@CR1]\]. The bDMARDs approved by the European Medicines Agency (EMA) and/or United States Food and Drug Administration (FDA) for use as monotherapy in the treatment of RA include the tumor necrosis factor (TNF) inhibitors adalimumab (ADA), certolizumab pegol (CZP), and etanercept (ETN), the T cell co-stimulation inhibitor abatacept (ABA), the interleukin (IL)-6 receptor (IL-6R)-blocking monoclonal antibodies (mAbs) sarilumab (SRL) and tocilizumab (TCZ), and the IL-1R-binding mAb anakinra (ANK). TOFA and BARI are also approved by the EMA and/or FDA for use as monotherapy in the treatment of RA \[[@CR2], [@CR3]\]. The IL-6-binding mAb sirukumab (SRK) was submitted to the FDA for approval as a treatment for RA, but this was declined \[[@CR4]\]. Infliximab and rituximab are not approved as monotherapy in RA.

Current European League Against Rheumatism (EULAR) recommendations for the treatment of RA support the use of MTX plus short-term glucocorticoids (GC) as a first-line treatment, with the aim of a greater than 50% improvement within 3 months and clinical remission within 6 months. If this fails, stratification based on disease prognosis is recommended. If there are no unfavorable prognostic markers (autoantibodies, high disease activity, early erosions, failure of two csDMARDs), patients should switch to or add another csDMARD. If unfavorable prognostic markers are present, a bDMARD or JAK inhibitor should be added to the csDMARD. If this also fails, switching to another bDMARD or tsDMARD is recommended \[[@CR5]\].

Despite EULAR recommendations suggesting that bDMARDs should be used in combination with MTX, it has been estimated that from just under one-quarter \[[@CR6], [@CR7]\] to approximately one-third \[[@CR8]--[@CR12]\] of patients prescribed a b/tsDMARD take it as monotherapy, without concomitant csDMARD therapy. Patients receiving bDMARDs as monotherapy generally fall into one of three groups---those who never begin treatment with a csDMARD such as MTX, as treatment is either contraindicated or declined (csDMARD-naïve), those who initiate MTX but subsequently discontinue \[csDMARD unresponsive or intolerant (csDMARD-U/I) or who do not adhere to their treatment\] \[[@CR10]\], and those who are in sustained remission and taper off csDMARD treatment. In the Danish study of patients on monotherapy, 70% of patients were on bDMARD monotherapy from biologic therapy initiation and 30% were on bDMARD monotherapy after stopping treatment with concomitant csDMARD \[[@CR6]\]. For both groups of patients, and their health care providers, knowing the efficacy of monotherapy versus combination therapy is of vital importance. Three recent systematic reviews have compared the efficacy of bDMARD monotherapy and tsDMARD monotherapy with MTX combination therapy in RA patients with an inadequate response to csDMARDs \[[@CR13]--[@CR15]\]. However, these reviews covered a limited number of randomized controlled trials (RCTs) and did not cover newer treatments such as BARI, SRL, and SRK. The relative benefit of one drug over another is also not fully known.

The objective of this systematic literature review (SLR) was to evaluate the clinical evidence regarding the efficacy of b/tsDMARD monotherapy in the treatment of RA, in order to help clinicians make the best treatment choices for their patients.

Methods {#Sec3}
=======

Search Methodology {#Sec4}
------------------

A comprehensive electronic search strategy of databases including MEDLINE, Embase, and the Cochrane database, executed on April 11, 2017, identified RCTs relevant to the study objectives. Controlled vocabulary and free-text terms were used and search results were filtered using the study designs of interest. In addition, a manual search of the American College of Rheumatology (ACR) and EULAR conference proceedings from 2010 to 2016 was undertaken to obtain recent studies not yet available as full-text articles. The full list of databases searched and the search strategies are listed in the Supplementary Materials, Tables 1--4.

This SLR was conducted using a standardized, thorough, and transparent approach, following Cochrane dual-reviewer methodology. The SLR protocol followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol guidelines. All processes and methodologies used to conduct this SLR are summarized below and described fully in the Supplementary Materials.

Study Selection and Data Extraction {#Sec5}
-----------------------------------

Studies were selected via a two-level screening process. At Level I, the titles and abstracts of publications identified in the literature searches were screened by one reviewer for eligibility according to the prespecified criteria described below. Any study not meeting all criteria was excluded. A second reviewer performed a quality check of a randomly selected 10% of all screened studies. The full text of publications that met eligibility criteria at Level I were retrieved for Level II screening. Any study found to be ineligible at Level II was excluded and the reason documented. An independent reviewer reviewed all publications eligible for inclusion and a randomly selected 20% of the publications excluded at Level II. Any discrepancies were resolved by a consensus among reviewers.

RCTs were eligible for inclusion, with non-randomized trials and observational studies, case reports, case series, and case studies being excluded. Previously published systematic/literature reviews, letters, commentaries, and editorials were also excluded, but were hand-searched for relevant studies that could be included in the current SLR. Studies were included if the participants were adults (≥ 18 years) diagnosed with RA according to a standardized diagnostic classification system (ACR 1987 or EULAR/ACR 2010 criteria). Studies were included if the bDMARDs or tsDMARDs listed in Table [1](#Tab1){ref-type="table"} were evaluated as monotherapy in the treatment of RA. For most treatments, only studies employing these drugs in dosage, form, and frequency of administration as recommended by health authorities \[such as National Institute for Health and Care Excellence (NICE)\], evidence-based clinical practice guidelines (ACR, EULAR, British Society for Rheumatology), or consensus statements from expert panels, were included. Studies evaluating treatments approved or submitted for approval from 2012 onwards (BARI, SRL, SRK, TOFA) were not restricted to recommended dosing regimens. Study information including efficacy outcomes, details of study design, treatment data, and patients' baseline demographic and clinical characteristics were extracted from each study that met eligibility criteria.Table 1List of included interventions and EMA/FDA recommended dosing intervalsSources: EMA \[[@CR2]\], FDA \[[@CR3]\]Generic nameAbbreviationAlternative namesRecommended label dose for RA (FDA unless otherwise stated)AbataceptABAOrencia^®^, bms-188667, CTLA4 igSc 125 mg at week 0, then every week (with or without an iv loading dose)AdalimumabADAHumira^®^Sc 40 mg every other week (40 mg every week may be considered)AnakinraANKKineret^®^Sc 100 mg per dayBaricitinibBARIOlumiant^®^EMA: 4 mg once dailyCertolizumab pegolCZPCimzia^®^, CDP 870, PHA738144Sc 400 mg at weeks 2 and 4, then 200 mg every other week (400 mg every 4 weeks may be considered)EtanerceptETNEnbrel^®^Sc 25 mg twice weekly or 50 mg weeklySarilumabSRLKevzara^®^Sc 200 mg once every 2 weeksSirukumab^a^SRKN/AN/ATocilizumabTCZActemra^®^, Atlizumab^®^, R1569, Roactemra^®^Iv 4 mg/kg at week 0, then 8 mg/kg every 4 weeks or sc 162 mg every other week, then every weekTofacitinibTOFACP690550, Jakvinus^®^, tasocitinib, Xeljanz^®^Oral 5 mg twice daily*EMA* European Medicines Agency,*FDA* United States Food and Drug Administration, *iv* intravenous, *N/A* not applicable, *RA* rheumatoid arthritis, *sc* subcutaneous^a^Since the literature search for this systematic literature review was completed, the application for FDA approval of sirukumab to treat RA has been rejected and the product has been discontinued \[[@CR4]\]

Risk of Bias Assessment {#Sec6}
-----------------------

The quality of RCTs was assessed using the recommendations from the NICE single technology appraisal manufacturer's template. RCTs were scored using the Jadad scoring system \[[@CR16]\]. The quality of abstracts from conference proceedings was assessed using a modified Downs and Black instrument \[[@CR17]\].

Compliance with Ethics Guidelines {#Sec7}
---------------------------------

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Results {#Sec8}
=======

Literature Search Results {#Sec9}
-------------------------

The electronic literature search yielded 18,949 articles, with some overlap between the MEDLINE^®^/Medline in process, Embase^®^, and Cochrane Library databases. After removing duplicate articles indexed on MEDLINE, Embase, and the Cochrane Library, there were 14,991 unique publications. A manual review of reference lists of review articles, conference proceedings, and recommendations from experts within the field identified an additional 63 publications. The screening process identified 44 studies reported in 71 publications and is illustrated in Fig. [1](#Fig1){ref-type="fig"}. Details of the studies included in this review are presented in Table [2](#Tab2){ref-type="table"}. The majority of the references were of excellent or good quality (Supplementary Tables 5 and 6). No publications for ANK met the inclusion criteria for this systematic review. Publications for SRK were included in this review as the application for FDA approval was rejected and the product discontinued after the literature search was completed. This search covered several treatment types including monotherapy versus combination therapy, monotherapy versus another drug (MTX or biologic therapy), or monotherapy versus placebo for each medication.Fig. 1Screening process Table 2List of included studies (44 studies in 71 publications)AuthorStudy namePatient populationStudy phaseInterventions and posology^a^Total number of patientsACR response rates at study end^b^SettingTreatment duration (weeks)ACR20%ACR50%ACR70%Emery et al. \[[@CR18]\]AVERTMTX-naïve or\
MTX ≤ 10 mg qw for ≤ 4 weeks, with no MTX ≥ 1 month prior to enrolment3bABA, sc, 125 mg qw; *n* = 116\
MTX (up to 20 mg qw); *n* = 116\
ABA, sc, 125 mg qw plus MTX (up to 20 mg qw); *n* = 119351ABA: 63.8\
MTX: 65.5\
ABA-MTX: 74.8ABA: 53.4\
MTX: 46.6\
ABA-MTX: 63.0ABA: 38.8\
MTX: 34.5\
ABA-MTX: 52.1Multicenter, multinational52Emery et al. \[[@CR19]\] (CA)NRNRNRBurmester et al. \[[@CR20]\] (CA)NRNRNRYazici et al. \[[@CR21]\] (CA)NRNRNRFurst et al. \[[@CR22]\] (CA)NRNRNRMoreland et al. \[[@CR23]\]--csDMARD-U/I or ETN-U/IPilotPBO, iv; *n* = 32\
ABA, iv, 10 mg/kg; *n* = 32214PBO: 31.6\
ABA: 53.3PBO: 6.3\
ABA: 15.7PBO: 0.0\
ABA: 6.3Multicenter, multinational12Breedveld et al. \[[@CR24]\]PREMIERMTX-naïve3ADA, sc, 40 mg q2w; *n* = 274\
MTX, oral, up to 20 mg qw; *n* = 257\
ADA, sc, 40 mg q2w plus MTX, oral, up to 20 mg qw; *n* = 268799ADA: 49\
MTX: 56\
ADA-MTX: 69\
*P* \< 0.001 combi vs ADA mono\
*P* = 0.002 combi vs MTX monoADA: 37\
MTX: 43\
ADA-MTX: 59\
*P* \< 0.001 combi vs either monoADA: 28\
MTX: 28\
ADA-MTX: 47\
*P* \< 0.001 combi vs either monoMulticenter, multinational104Miyasaka et al. \[[@CR25]\]CHANGEcsDMARD-U/I2/3PBO, sc, q2w; *n* = 87\
ADA, sc, 40 mg q2w; *n* = 91352PBO: 13.8\
ADA: 44.0\
*P* \< 0.001PBO: 5.7\
ADA: 24.2\
*P* \< 0.05PBO: 1.1\
ADA: 12.1\
*P* \< 0.05Multicenter (Japan)24van de Putte et al. \[[@CR26]\]--csDMARD-U/I3PBO, sc, qw; *n* = 110\
ADA, sc, 40 mg qw; *n* = 103\
ADA, sc, 40 mg q2w; *n* = 113544PBO: 19.1\
ADA 40 mg qw: 53.4\
ADA 40 mg q2w: 46.0\
*P* \< 0.001 ADA vs PBOPBO: 8.2\
ADA 40 mg qw: 35.0\
ADA 40 mg q2w: 22.1\
*P* \< 0.001 ADA qw vs PBO\
*P* \< 0.05 ADA q2w vs PBOPBO: 1.8\
ADA 40 mg qw: 18.4\
ADA 40 mg q2w: 12.4\
*P* \< 0.001 ADA qw vs PBO\
*P* \< 0.05 ADA q2w vs PBOMulticenter, multinational26Fleischmann et al. \[[@CR27]\]--csDMARD-U/I2bPBO, oral, bid; *n* = 59\
TOFA, oral, 1 mg bid; *n* = 54\
TOFA, oral, 3 mg bid; *n* = 51\
TOFA, oral, 5 mg bid; *n* = 49\
TOFA, oral, 10 mg bid; *n* = 61\
TOFA, oral, 15 mg bid; *n* = 57\
ADA, sc, 40 mg q2w, BL-10 weeks then TOFA, oral, 5 mg, 12--24 weeks; *n* = 53384NRNRNRMulticenter, multinational24Popa et al. \[[@CR28]\]--DMARD-experienced1PBO; *n* = 13\
ADA; *n* = 33 (dose information not available)46NRNRNRSingle center2Gabay et al. \[[@CR29]\]ADACTAMTX-U/I4ADA, sc, 40 mg q2w; *n* = 163\
TCZ, iv, 8 mg/kg q4w; *n* = 163326ADA: 49.4\
TCZ: 65.0\
*P* = 0.004ADA: 27.8\
TCZ: 47.2\
*P* \< 0.001ADA: 17.9\
TCZ: 32.5\
*P* = 0.002Multicenter, multinational24Strand et al. \[[@CR30]\] (CA)NRNRNRNRNRNRBurmester et al. \[[@CR31]\] (CA)MONARCHMTX-U/I3ADA, sc, 40 mg q2w; *n* = 185\
SRL, sc, 200 mg q2w; *n* = 184369ADA: 58.4\
SRL: 71.7\
*P* = 0.007ADA: 29.7\
SRL: 45.7\
*P* = 0.002ADA: 11.9\
SRL: 23.4\
*P* = 0.004Multicenter, multinational24Burmester et al. \[[@CR32]\]NRNRNRTaylor et al. \[[@CR33]\] (CA)SIRROUND-HMTX-U/I\
MTX-naïve3ADA, sc, 40 mg q2w; *n* = 186\
SRK, sc, 50 mg q4w; *n* = 186\
SRK, sc, 100 mg q2w; *n* = 187559ADA: 56.5\
SRK 50 mg: 53.8\
SRK 100 mg: 58.8ADA: 31.7\
SRK 50 mg: 26.9\
SRK 100 mg: 35.3NRGlobal24Fleischmann et al. \[[@CR34]\] (CA)RA-BEGINcsDMARD-naïve (≤ 3 weekly MTX doses permitted)3BARI, 4 mg qd; *n* = 159\
MTX, up to 20 mg qw; *n* = 210\
BARI, 4 mg qd plus MTX up to 20 mg qw; *n* =215584BARI: 77\
MTX: 62\
BARI-MTX: 78BARI: 60\
MTX: 43\
BARI-MTX: 63BARI: 42\
MTX: 21\
BARI-MTX: 40Multicenter, multinational24*P* ≤ 0.01 BARI vs MTX*P* ≤ 0.01 BARI vs MTX*P* ≤ 0.001 BARI/combi vs MTX*P* ≤ 0.001 combi vs MTX*P* ≤ 0.001 combi vs MTXFleischmann et al. \[[@CR35]\]NRNRNR52Weinblatt et al. \[[@CR36]\]REALISTICcsDMARD-U/I3bPBO, sc, q2w; *n* = 212\
CZP 200 mg, sc, q2w (following initial dosing of 400 mg) with or without MTX; *n* = 8511063PBO: 25.9\
CZP: 51.1\
*P* \< 0.001PBO: 9.9\
CZP: 26.6\
*P* \< 0.001PBO: 2.8\
CZP: 12.9\
*P* \< 0.001Multicenter, multinational12Yamamoto et al. \[[@CR37]\]HIKARIMTX-U/I3PBO, q2w; *n* = 114\
CZP 200 mg, q2w (following initial dosing at weeks 0, 2, 4 with 400 mg) ± non-MTX DMARD; *n* = 116230NRNRNRJapan24Fleischmann et al. \[[@CR38]\]FAST4WARDcsDMARD-U/I3PBO, sc, q4w; *n* = 109\
CZP, sc, 400 mg q4w; *n* = 111220PBO: 9.3\
CZP: 45.5\
*P* \< 0.001PBO: 3.7\
CZP: 22.7\
*P* \< 0.001PBO: 0.0\
CZP: 5.5\
*P* \< 0.05Multicenter, multinational24Johnsen et al. \[[@CR39]\]--csDMARD-U/INRETN, sc, 25 mg bw; *n* = 2677ETN: 65ETN: 38ETN: 15Multicenter (USA)24Combe et al. \[[@CR40]\]--SSZ-U/INRETN, sc, 25 mg bw; *n* = 103\
SSZ (2, 2.5, or 3 g qd); *n* =50\
ETN, sc, 25 mg bw plus SSZ (2, 2.5, 3 g qd); *n* = 101254ETN: 73.8\
SSZ: 28.0\
ENT-SSZ: 74\
*P* \< 0.05 SSZ vs combi or ETNETN: 46.6\
SSZ: 14.0\
ETN-SSZ: 52.0\
*P* \< 0.05 SSZ vs combi or ETNETN: 21.4\
SSZ: 2.0\
ETN-SSZ: 25.0\
*P* \< 0.05 SSZ vs combi or ETNMulticenter24Combe et al. \[[@CR41]\]ETN: 67.0\
SSZ: 33.7\
ETN-SSZ: 77.2\
*P* \< 0.01 SSZ vs combi\
*P* \< 0.05 SSZ vs ETNETN: 46.8\
SSZ: 10.3\
ETN-SSZ: 58.7\
*P* \< 0.01 SSZ vs combi\
*P* \< 0.05 SSZ vs ETNETN: 24.4\
SSZ: 2.0\
ETN-SSZ: 28.1\
*P* \< 0.01 SSZ vs combi\
*P* \< 0.05 SSZ vs ETN104Kameda et al. \[[@CR42]\] (CA)JESMRMTX-U/I4ETN, sc, 25 mg bw; *n* = 74\
ETN, sc, 25 mg bw plus MTX (6--8 mg qw); *n* = 77151NRNRNRMulticenter (Japan)104Kameda et al. \[[@CR43]\]ETN: 63.8\
ETN-MTX: 90.4\
*P* \< 0.001ETN: 47.8\
ETN-MTX: 64.4ETN: 26.1\
ETN-MTX: 38.424Klareskog et al. \[[@CR44]\]TEMPOcsDMARD-U/I3ETN, sc, 25 mg bw; *n* = 223\
MTX, oral, up to 20 mg qw; *n* = 228\
ETN, sc, 25 mg bw plus MTX, oral, up to 20 mg qw; *n* = 231682ETN: 76\
MTX: 75\
ETN-MTX: 85\
*P* = 0.009 combi vs MTX\
*P* = 0.015 combi vs ETNETN: 48\
MTX: 43\
ETN-MTX: 63\
*P* \< 0.001 combi vs MTX or ETNETN: 24\
MTX: 19\
ETN-MTX: 43\
*P* \< 0.001 combi vs MTX or ETNMulticenter (multinational)52van der Heijde et al. \[[@CR45]\]ETN: 75\
MTX: 71\
ETN-MTX: 86\
*P* \< 0.01 combi vs MTX or ETNETN: 54\
MTX: 42\
ETN-MTX: 71\
*P* \< 0.01 combi vs MTX or ETNETN: 27\
MTX: 21\
ETN-MTX: 49\
*P* \< 0.01 combi vs MTX or ETN104van der Heijde et al. \[[@CR46]\]ETN: 70.9\
MTX: 70.2\
ETN-MTX: 85.3\
*P* \< 0.01 combi vs MTX or ETNETN: 45.7\
MTX: 43.9\
ETN-MTX: 67.1\
*P* \< 0.01 combi vs MTX or ETNETN: 26.0\
MTX: 21.1\
ETN-MTX: 47.2\
*P* \< 0.01 combi vs MTX or ETN156Moreland et al. \[[@CR47]\]--csDMARD-U/I3PBO, sc, bw; *n* = 80\
ETN, sc, 25 mg bw; *n* = 78234PBO: 11\
ETN: 59\
*P* \< 0.001PBO: 5\
ETN: 40\
*P* \< 0.001PBO: 1\
ETN: 15\
*P* \< 0.031Multicenter (North America)26Mathias et al. \[[@CR48]\]NRNRNRBathon et al. \[[@CR49]\]ENBREL ERAMTX-naïveNRETN, sc, 25 mg bw; *n* = 207\
MTX, oral, 7.5 mg qw; *n* = 217632ETN: 72\
MTX: 65NRNRNR52Hu et al. \[[@CR50]\]--csDMARD-experiencedNRETN, sc, 25 mg bw; *n* = 118\
MTX, oral, up to 15 mg qw; *n* = 120238ETN: 75.4\
MTX: 70.0ETN: 40.7\
MTX: 30.8ETN: 20.3\
MTX: 10.8\
*P* = 0.042Multicenter (China)24Takeuchi et al. \[[@CR51]\]--csDMARD-U/I3ETN, sc, 25 mg bw; *n* = 182\
MTX, oral, 6--8 mg qw; *n* = 176550ETN: 78.6\
MTX: 62.5\
*P* \< 0.001ETN: 62.1\
MTX: 36.9\
*P* \< 0.001ETN: 36.3\
MTX: 15.9\
*P* \< 0.001Multicenter (Japan)52Genovese et al. \[[@CR52]\]--MTX-U/INRETN, sc, 25 mg bw; *n* = 80\
ETN, sc, 25 mg bw plus ANK, 100 mg, qd; *n* = 81242ETN: 68\
ETN-ANK: 62\
*P* = 0.037ETN: 41\
ETN-ANK: 31ETN: 21\
ETN-ANK: 14Multicenter (USA)24Weinblatt et al. \[[@CR53]\]--csDMARD-experienced2ETN, sc, 25 mg bw; *n* = 36\
ETN, sc, 25 mg bw plus ABA, iv, 2 mg/kg; *n* = 85121NRNRNRMulticenter (USA)156Burmester et al. \[[@CR31]\] (CA)MONARCHMTX-U/I3ADA, sc, 40 mg q2w; *n* = 185\
SRL, sc, 200 mg q2w; *n* = 184369ADA: 58.4\
SRL: 71.7\
*P* = 0.007ADA: 29.7\
SRL: 45.7\
*P* = 0.002ADA: 11.9\
SRL: 23.4\
*P* = 0.004Multicenter, multinational24Burmester et al. \[[@CR32]\]ADA: 58.4\
SRL: 71.7\
*P* ≤ 0.007ADA: 29.7\
SRL: 45.7\
*P* ≤ 0.007ADA: 11.9\
SRL: 23.4\
*P* ≤ 0.007Takeuchi et al. \[[@CR54]\] (CA)--NRNRSRK, 50 mg q4w; *n* = 56\
SRK, 100 mg q2w; *n* = 58122NRNRNRJapan52Takeuchi et al. \[[@CR55]\] (CA)SIRROUND-DcsDMARD-U/I3PBO, sc, q2w; *n* = 556\
SRK, sc, 50 mg q4w; *n* =557\
SRK, sc, 100 mg q2w; *n* = 5571670NRNRNRGlobal52Aletaha et al. \[[@CR56]\]SIRROUND-TcsDMARD-U/I\
csDMARD-naïve3PBO, sc, q2w; *n* = 294\
SRK, sc, 50 mg q4w; *n* =292\
SRK, sc, 100 mg q2w; *n* = 292878PBO: 26\
SRK 50 mg q4w: 43\
SRK 100 mg q2w: 43\
*P* \< 0.001 SRK vs PBOPBO: 9\
SRK 50 mg q4w: 21\
SRK 100 mg q2w: 22\
*P* \< 0.001 SRK vs PBOPBO: 4\
SRK 50 mg q4w: 9\
SRK 100 mg q2w: 10\
*P* = 0.026 SRK 100 mg q2w vs PBO\
*P* = 0.006 SRK 50 mg q4w vs PBOGlobal24Taylor et al. \[[@CR33]\] (CA)SIRROUND-HMTX-U/I\
MTX-naïve3ADA, sc, 40 mg q2w; *n* = 186\
SRK, sc, 50 mg q4w; *n* =186\
SRK, sc, 100 mg q2w; *n* = 187559ADA: 56.5\
SRK 50 mg q4w: 53.8\
SRK 100 mg q2w: 58.8ADA: 31.7\
SRK 50 mg q4w: 26.9\
SRK 100 mg q2w: 35.3NRGlobal24Burmester et al. \[[@CR57]\] (CA)FUNCTIONMTX-naïve3TCZ, iv, 8 mg/kg q4w; *n* = 292\
MTX, up to 7.5--20 mg qw; *n* = 289\
TCZ, iv, 8 mg/kg q4w plus MTX, up to 20 mg qw; *n* = 2911162NRNRNRNR52Burmester et al. \[[@CR58]\] (CA)TCZ: 61.6\
MTX: 25.4\
TCZ-MTX: 65.2TCZ: 53.1\
MTX: 22.0\
TCZ-MTX: 57.6TCZ: 39.4\
MTX: 17.4\
TCZ-MTX: 46.6104Burmester et al. \[[@CR59]\]TCZ: 62.7\
MTX: 56.7\
TCZ-MTX: 66.8\
*P* = 0.012 MTX vs combiTCZ: 49.1\
MTX: 40.7\
TCZ-MTX: 55.6\
*P* \< 0.001 MTX vs combi\
*P* = 0.036 MTX vs TCZTCZ: 35.8\
MTX: 28.8\
TCZ-MTX: 42.8\
*P* \< 0.001 MTX vs combi52Burmester et al. \[[@CR60]\] (CA)FUNCTION\
AMBITIONMTX-naïve3TCZ, iv, 8 mg/kg; *n* = 408\
MTX, oral; *n* = 412820FUNCTION\
MTX: 65.2\
TCZ: 70.2\
AMBITION\
MTX: 60.0\
TCZ: 73.3FUNCTION\
MTX: 43.2\
TCZ: 47.6\
AMBITION\
MTX: 40.8\
TCZ: 53.4FUNCTION\
MTX: 25.4\
TCZ: 30.1\
AMBITION\
MTX: 19.2\
TCZ: 35.3NR24Weinblatt et al. \[[@CR61]\]ACT-STARcsDMARD-U/I3bTCZ, iv, 8 mg/kg q4w; *n* = 163\
TCZ, iv, 8 mg/kg q4w, plus csDMARD; *n* = 360886TCZ: 40.5\
TCZ-DMARD: 38.0TCZ: 16.4\
TCZ-DMARD: 12.0TCZ: 4.8\
TCZ-DMARD: 4.1Multicenter (USA)24Takeuchi et al. \[[@CR62]\] (CA)SURPRISEMTX-U/INRTCZ switch, iv, 8 mg/kg q4w; *n* = 115\
MTX, 15 mg qw, plus TCZ add-on, iv, 8 mg/kg q4w; *n* = 118233TCZ: 66.7\
TCZ-MTX: 64.3TCZ: 53.2\
TCZ-MTX: 48.7TCZ: 36.0\
TCZ-MTX: 27.8Multicenter (Japan)24Dougados et al. \[[@CR63]\]ACT-RAYMTX-experiencedNRTCZ switch, iv, 8 mg/kg q4w; *n* = 277\
MTX, 15 mg qw, plus TCZ add-on, iv, 8 mg/kg q4w; *n* = 279556TCZ: 70.3\
TCZ-MTX: 71.5TCZ: 40.2\
TCZ-MTX: 45.5TCZ: 25.4\
TCZ-MTX: 24.5Multicenter24Herold et al. \[[@CR64]\] (CA)OPTIMISEMTX-U/INRTCZ, iv, 8 mg/kg q4w; *n* = 33\
TCZ, iv, 8 mg/kg q4w plus MTX, sc, 15--25 mg qw; *n* = 3065NRNRNRAustria24Pablos et al. \[[@CR65]\] (CA)--csDMARD-U/I3TCZ, iv, 8 mg/kg q4w; *n* = 82\
TCZ, iv, 8 mg/kg q4w plus MTX, oral; *n* = 83165NRNRNRNR44Nishimoto et al. \[[@CR66]\]STREAMcsDMARD-U/I2PBO, iv, q4w; *n* = 53\
TCZ, iv, 8 mg/kg q4w; *n* = 55162PBO: 11.3\
TCZ: 78.2\
*P* \< 0.001PBO: 1.9\
TCZ: 40.0\
*P* \< 0.001PBO: 0.0\
TCZ: 16.4\
*P* = 0.002Multicenter (Japan)12Ogata et al. \[[@CR67]\]MUSASHIcsDMARD-U/I3TCZ, iv, 8 mg/kg q4w; *n* = 173\
TCZ, sc, 162 mg q2w; *n* = 173346TCZ iv: 86.0\
TCZ sc: 79.2NRNRMulticenter (Japan)24Ogata et al. \[[@CR68]\]TCZ iv: 84.5\
TCZ sc: 76.2TCZ iv: 61.8\
TCZ sc: 57.7TCZ iv: 37.7\
TCZ sc: 34.9Ogata et al. \[[@CR69]\] (CA)--NRNRTCZ, sc, 162 mg qw; *n* = 21\
TCZ, sc, 162 mg q2w; *n* = 2142TCZ qw: 52.4\
TCZ q2w: 20.0TCZ qw: 38.1\
TCZ q2w: 15.0TCZ qw: 14.3\
TCW q2w: 15.0Japan12Durez et al. \[[@CR70]\]TOMERAMTX-naïveNRTCZ, iv, 8 mg/kg q4w; *n* = 17\
MTX, 20 mg/wk; *n* = 1330NRNRNRNR76Jones et al. \[[@CR71]\]AMBITIONNot MTX-U/INRTCZ, iv, 8 mg/kg q4w; *n* = 288\
MTX, sc, up to 20 mg qw; *n* = 284673TCZ: 69.9\
MTX: 52.6TCZ: 44.1\
MTX: 33.5TCZ: 28.0\
MTX: 15.0Multicenter (multinational)24Nishimoto et al. \[[@CR72]\]SAMURAIcsDMARD-U/INRTCZ, iv, 8 mg/kg q4w; *n* = 157\
csDMARD therapy; *n* = 145302TCZ: 78\
csDMARD: 34\
*P* \< 0.001TCZ: 64\
csDMARD: 13\
*P* \< 0.001TCZ: 44\
csDMARD: 6\
*P* \< 0.001Multicenter (Japan)52Kawashiri et al. \[[@CR73]\]TCZ, iv, 8 mg/kg q4w; *n* = 9\
csDMARD therapy; *n* = 1019NRNRNR12Nishimoto et al. \[[@CR74]\]SATORIMTX-U/INRTCZ, iv, 8 mg/kg q4w; *n* = 61\
MTX, sc, 8 mg qw; *n* = 64125TCZ: 84.1\
MTX: 35.1TCZ: 54.0\
MTX: 15.9TCZ: 32.2\
MTX: 10.9Multicenter (Japan)24Gabay et al. \[[@CR29]\]ADACTAMTX-U/I4ADA, sc, 40 mg q2w; *n* = 163\
TCZ, iv, 8 mg/kg q4w; *n* = 163326ADA: 49.4\
TCZ: 65.0\
*P* = 0.004ADA: 27.8\
TCZ: 47.2\
*P* \< 0.001ADA: 17.9\
TCZ: 32.5\
*P* = 0.002Multicenter, multinational24Strand et al. \[[@CR30]\] (CA)AMBITION\
ADACTAMTX-naïve (AMBITION)\
MTX-U/I (ADACTA)NRTCZ, iv, 8 mg/kg q4w; *n* = 265\
MTX, sc, up to 20 mg qw; *n* = 259\
(AMBITION)\
ADA, sc, 40 mg q2w; *n* = 162\
TCZ, iv, 8 mg/kg q4w; *n* = 163\
(ADACTA)NRNRNRNRNR24Fleischmann et al. \[[@CR75]\]ORAL SOLODMARD-U/I3PBO, 13 weeks then TOFA, oral 5 mg bid for 13 weeks; *n* = 61\
PBO, 13 weeks then TOFA, oral 10 mg bid for 13 weeks; *n* = 61\
TOFA, oral 5 mg qd for 26 weeks; *n* = 243\
TOFA, oral 10 mg qd for 26 weeks; *n* = 245610PBO → TOFA 5 mg: 60\
TOFA 5 mg: 68NRNRMulticenter, multinational26Strand et al. \[[@CR76]\]NRNRNRTanaka et al. \[[@CR77]\] (CA)--csDMARD-U/I2bPBO, oral, bid; *n* = 52\
TOFA, oral, 1 mg bid; *n* = 53\
TOFA, oral, 3 mg bid; *n* = 53\
TOFA, oral, 5 mg bid; *n* = 52\
TOFA, oral, 10 mg bid; *n* = 53\
TOFA, oral, 15 mg bid; *n* = 54317PBO: 15.4\
TOFA 5 mg: 73.1\
*P* \< 0.001PBO: 7.7\
TOFA 5 mg: 46.2\
*P* \< 0.001PBO: 1.9\
TOFA 5 mg: 26.9\
*P* \< 0.05Japan12Tanaka et al. \[[@CR78]\]2PBO: 15.4\
TOFA 5 mg: 73.1\
*P* \< 0.001PBO: 7.8\
TOFA 5 mg: 45.6\
*P* \< 0.05PBO: 2.4\
TOFA 5 mg: 26.7\
*P* \< 0.05Kremer et al. \[[@CR79]\]--MTX-U/I2aPBO, bid; *n* = 65\
TOFA, oral, 5 mg bid; *n* = 61\
TOFA, oral, 15 mg bid; *n* = 69\
TOFA, oral, 30 mg bid; *n* = 69264PBO: 29.2\
TOFA 5 mg: 70.5\
*P* \< 0.001PBO: 6.2\
TOFA 5 mg: 33.0\
*P* \< 0.001PBO: 3.1\
TOFA 5 mg: 13.3\
*P* \< 0.05Multicenter, multinational6Fleischmann et al. \[[@CR80]\] (CA)ORAL STARTMTX-naïve3TOFA, oral, 5 mg bid; *n* = 373\
TOFA, oral, 10 mg bid; *n* = 397\
MTX, 10--20 mg qw; *n* = 186956NRTOFA 5 mg: 50\
MTX: 32TOFA 5 mg: 28\
MTX: 15Multicenter, multinational24Fleischmann et al. \[[@CR81]\] (CA)NRTOFA 5 mg: 50\
MTX: 32TOFA 5 mg: 28\
MTX: 1524Lee et al. \[[@CR82]\] (CA)TOFA: 71.0\
MTX: 50.5\
*P* \< 0.001TOFA: 46.6\
MTX: 27.2\
*P* \< 0.001TOFA: 25.5\
MTX: 12.0\
*P* \< 0.00152Fleischmann et al. \[[@CR83]\] (CA)Early RA\
TOFA: 68.9\
MTX: 47.2\
Established RA\
TOFA: 58.2\
MTX: 36.8\
All *P* \< 0.05Early RA\
TOFA: 54.1\
MTX: 32.1\
Established RA\
TOFA: 42.9\
MTX: 23.7\
All *P* \< 0.05Early RA\
TOFA: 40.8\
MTX: 15.1\
Established RA\
TOFA: 26.5\
MTX: 15.8\
All *P* \< 0.05104Fleischmann et al. \[[@CR84]\]Early RA\
TOFA: 68.8\
MTX: 47.3\
*P* \< 0.001\
Established RA\
TOFA: 58.2\
MTX: 36.8\
*P* \< 0.01Early RA\
TOFA: 54.0\
MTX: 32.0\
*P* \< 0.001\
Established RA\
TOFA: 43.0\
MTX: 23.5\
*P* \< 0.01Early RA\
TOFA: 40.9\
MTX: 15.0\
*P* \< 0.001\
Established RA\
TOFA: 26.5\
MTX: 15.8\
*P* \< 0.05104Alten et al. \[[@CR85]\] (CA)NRNRNR104Strand et al. \[[@CR86]\]NRNRNR104Strand et al. \[[@CR87]\] (CA)NRNRNR104Charles-Schoeman et al. \[[@CR88]\] (CA)TOFA 5 mg +GC: 65.2\
TOFA 5 mg --GC: 62.7\
MTX +GC: 49.4\
MTX --GC: 37.1\
*P* \< 0.05 TOFA vs MTX within subgroupTOFA 5 mg +GC: 50.8\
TOFA 5 mg --GC: 47.0\
MTX +GC: 31.8\
MTX --GC: 25.8\
*P* \< 0.05 TOFA vs MTX within subgroupTOFA 5 mg +GC: 34.3\
TOFA 5 mg --GC: 34.1\
MTX +GC: 14.1\
MTX --GC: 16.5\
*P* \< 0.05 TOFA vs MTX within subgroup104Fleischmann et al. \[[@CR27]\]--csDMARD-U/I2bPBO, oral, bid; *n* = 59\
TOFA, oral, 1 mg bid; *n* = 54\
TOFA, oral, 3 mg bid; *n* = 51\
TOFA, oral, 5 mg bid; *n* = 49\
TOFA, oral, 10 mg bid; *n* = 61\
TOFA, oral, 15 mg bid; *n* = 57\
ADA, sc, 40 mg q2w, BL-10 weeks then TOFA, oral, 5 mg, 12--24 weeks; *n* = 53384PBO: 25.4\
TOFA 5 mg: 51.0\
*P* ≤ 0.05PBO: 10.2\
TOFA 5 mg: 34.7\
*P* ≤ 0.05PBO: 6.8\
TOFA 5 mg: 20.4\
*P* ≤ 0.05Multicenter, multinational24*ABA* abatacept,*ACR* American College of Rheumatology, *ADA* adalimumab, *bid* twice a day, *BL* study baseline, *bw* twice a week, *CA* conference abstract, *csDMARD* conventional synthetic disease-modifying antirheumatic drug, *CZP* certolizumab pegol, *ETN* etanercept, *GC* glucocorticoids, *iv* intravenous, *MTX* methotrexate, *NR* not reported, *nRCT* non-randomized controlled trial, *PBO* placebo, *q2w* once every 2 weeks, *q4w* once every 4 weeks, *qd* once a day, *qw* once a week,*RA* rheumatoid arthritis, *RCT* randomized controlled trial, *sc* subcutaneous,*SRK* sirukumab,*SRL* sarilumab, *SSZ* sulfasalazine, *TCZ* tocilizumab, *TNFi* tumor necrosis factor inhibitor, *TOFA* tofacitinib, *U/I* unresponsive/intolerant^a^Only recommended doses (see Table [1](#Tab1){ref-type="table"}) are listed for ABA, ADA, CZP, ETN, and TCZ^b^Significant *P* values are presented where available

Abatacept Monotherapy {#Sec10}
---------------------

Six publications comprising two RCTs provided data on the efficacy of ABA monotherapy (Table [2](#Tab2){ref-type="table"}) \[[@CR18]--[@CR23]\]. When ABA monotherapy was compared with ABA + MTX combination therapy in the AVERT study of MTX-naïve patients \[[@CR18]--[@CR22]\], ABA + MTX combination therapy showed higher rates of disease activity score in 28 joints (DAS28) \[C-reactive protein (CRP)\]-defined remission and other efficacy outcomes than ABA monotherapy. When ABA monotherapy was compared with MTX monotherapy, a similar proportion of patients achieved DAS28(CRP)-defined remission at 12 months of treatment \[subcutaneous (sc) ABA: 48/113 (42.5%) versus MTX: 52/115 (45.2%)\], although DAS28(CRP)-defined remission rates were numerically higher for ABA monotherapy at early time points. Additionally, ABA monotherapy demonstrated numerically higher ACR20/50/70 rates versus MTX over time \[[@CR18]\]. Compared with placebo, intravenous (iv) ABA (10 mg/kg) was associated with improvement in ACR20/50/70 responses, tender and swollen joint counts, patient assessment of disease activity, physician assessments of pain/disease activity, and CRP and erythrocyte sedimentation rate (ESR) scores in one 24-week study in csDMARD-U/I patients \[[@CR23]\].

Adalimumab Monotherapy {#Sec11}
----------------------

Ten publications comprising nine RCTs, predominantly in csDMARD-U/I patients, provided data on the efficacy of ADA monotherapy (Table [2](#Tab2){ref-type="table"}). Only the PREMIER study in MTX-naïve patients compared ADA + MTX combination therapy to ADA and MTX monotherapies \[[@CR24]\]. After 104 weeks of treatment, ACR20/50/70 response rates and DAS28(CRP) remission rates were significantly higher with ADA + MTX combination therapy than with ADA monotherapy (all *P* \< 0.001), while ADA and MTX monotherapies were similar. Treatment discontinuation due to lack of efficacy was higher with ADA monotherapy than with MTX monotherapy or ADA + MTX combination therapy \[[@CR24]\].

Compared with placebo, sc ADA monotherapy was associated with statistically significant improvements in ACR20/50/70 compared with placebo over 12--26 weeks in two studies \[[@CR25], [@CR26]\]; a third study also showed improvements in ACR20/50/70 compared with placebo over 12 weeks although this was non-significant \[[@CR27]\]. A fourth study showed a rapid (2-week) clinical improvement in DAS with ADA versus placebo \[[@CR28]\]. One study of ADA versus placebo reported that treatment discontinuation due to lack of efficacy was greater in the placebo group compared with the ADA monotherapy groups (significance not reported) \[[@CR26]\].

Seven studies compared sc ADA with another treatment \[[@CR24], [@CR26], [@CR27], [@CR29]--[@CR33]\]. Two publications from the ADACTA study compared sc ADA head-to-head with iv TCZ. ACR20/50/70 response rates and improvements in DAS28, physician global assessment (PGA), and the number of patients in DAS28(ESR) remission, Clinical Disease Activity Index (CDAI) remission, and with a good EULAR response were significantly greater with TCZ than ADA \[[@CR29], [@CR30]\]. Two publications from the MONARCH study compared sc ADA head-to-head with sc SRL \[[@CR31], [@CR32]\]. At 24 weeks, ACR20/50/70 response rates and improvements in Health Assessment Questionnaire (HAQ) score, DAS28(ESR) remission, and CDAI remission were significantly greater with SRL than ADA \[[@CR31]\]. One publication from the SIRROUND-H study compared sc ADA with sc SRK \[[@CR33]\]. ACR20/50 response rates were similar for ADA and SRK; however, patients receiving 100 mg once every 2 weeks (q2w) SRK \[but not 50 mg once every 4 weeks (q4w)\] had significantly better DAS28(ESR) change from baseline and DAS28(ESR) remission at 24 weeks than patients receiving ADA. The final study compared sc ADA to placebo and oral TOFA to placebo \[[@CR27]\]. At 12 weeks, ACR/20/50/70 response rates, change in DAS28, and DAS28(ESR) remission rates were higher for ≥ 5 mg twice daily (bid) TOFA than for ADA, although the study was not powered to directly compare the two treatments.

Baricitinib Monotherapy {#Sec12}
-----------------------

Two publications from the RA-BEGIN study in MTX-naïve patients (or patients who had received fewer than 3 weekly MTX doses) provided data on the efficacy of BARI monotherapy (Table [2](#Tab2){ref-type="table"}). Patients receiving BARI + MTX combination therapy or BARI monotherapy were significantly more likely to achieve an ACR20/50/70 response than patients receiving MTX (*P* ≤ 0.01), but ACR response rates were similar for BARI + MTX combination therapy and BARI monotherapy. The percentage of patients in DAS28(ESR) remission was significantly higher for BARI + MTX combination therapy (*P* ≤ 0.01) and BARI monotherapy (*P* ≤ 0.05) than for MTX monotherapy \[[@CR34], [@CR35]\]. However, change in total Sharp score from study baseline was only significantly higher than MTX monotherapy (*P* ≤ 0.05) for BARI + MTX combination therapy, not for BARI monotherapy \[[@CR35]\].

Certolizumab Pegol Monotherapy {#Sec13}
------------------------------

Three publications from three RCTs in csDMARD-U/I patients provided data on the efficacy of CZP monotherapy (Table [2](#Tab2){ref-type="table"}). The REALISTIC study in csDMARD-U/I patients compared patients receiving CZP monotherapy with those receiving CZP + csDMARDs at study baseline. Compared with patients receiving CZP + 1 or ≥ 2 concomitant csDMARDs at baseline, patients receiving CZP monotherapy had lower ACR20/50/70 response rates but slightly greater change in DAS28 (CRP and ESR) scores from baseline, but results were not statistically significant \[[@CR36]\]. The HIKARI study of MTX-naïve patients included patients receiving CZP with or without non-MTX csDMARD therapy. ACR20 response rates at 12 weeks were 67.2% for CZP monotherapy versus 14.9% for placebo \[[@CR37]\].

Patients receiving CZP monotherapy were more likely to achieve an ACR20/50/70 response than patients receiving placebo \[[@CR36]--[@CR38]\]. Significantly more patients in the placebo group discontinued treatment because of a lack of efficacy than in the CZP monotherapy group (*P* \< 0.001) \[[@CR38]\]. The REALISTIC study showed that ACR20/50/70 response rates and change in DAS28 (CRP) from baseline were significantly higher with CZP monotherapy than with placebo after 12 weeks of treatment \[[@CR36]\].

Etanercept Monotherapy {#Sec14}
----------------------

Fifteen publications from 10 RCTs, predominantly in csDMARD-U/I patients, provided data on the efficacy of ETN monotherapy (Table [2](#Tab2){ref-type="table"}). The first study demonstrated the efficacy of 25 mg ETN monotherapy taken twice a week, but there was no placebo or active comparator of approved dose in this study \[[@CR39]\].

Three studies directly compared ETN monotherapy with ETN + csDMARD combination therapy \[[@CR40]--[@CR46]\]. ACR20/50/70 responses were significantly greater with ETN + MTX combination therapy than with ETN monotherapy at 52 weeks (*P* = 0.003/= 0.001/= 0.005) \[[@CR42]\] and 3 years (all *P* \< 0.01) \[[@CR46]\] as were numbers of patients achieving DAS or DAS28 remission \[[@CR43]--[@CR46]\]. In an ETN + sulfasalazine (SSZ) treatment study, combination therapy was not significantly more effective than ETN monotherapy for ACR20/50/70 response rates at 24 or 104 weeks \[[@CR41]\], or for mean DAS28 score at 24 weeks, but was significantly more effective for mean DAS28 score at 104 weeks \[[@CR40], [@CR41]\].

In a study comparing ETN monotherapy with placebo \[[@CR47], [@CR48]\], ACR20/50/70 response rates were significantly higher for ETN than for placebo at 3 and 6 months, as were improvements in Tender Joint Count (TJC), Swollen Joint Count (SJC), HAQ (3 and 6 months), and PGA (12 weeks). At 6 months, significantly more patients receiving placebo had discontinued because of a lack of treatment efficacy than patients receiving ETN \[[@CR47]\].

Three studies compared the efficacy of ETN monotherapy with csDMARD monotherapy \[[@CR49]--[@CR51]\]: one study was in MTX-naïve patients, one in csDMARD-experienced patients, and one in csDMARD-U/I patients. In these three studies, significantly more patients achieved ACR20/50/70 responses with ETN monotherapy than with MTX over 6 months (*P* \< 0.05) \[[@CR49]--[@CR51]\] (although for one study the difference between treatments was only seen with cumulative response over time) \[[@CR49]\].

Finally, two studies compared sc ETN monotherapy with either ETN-ANK \[[@CR52]\] (6 months) or ETN-ABA \[[@CR53]\] (12 months) combination therapy. Neither combination provided treatment benefit over ETN monotherapy \[[@CR52], [@CR53]\].

Sarilumab Monotherapy {#Sec15}
---------------------

No publications compared SRL monotherapy with SRL + csDMARD combination therapy. Two publications from the MONARCH study provided data on the efficacy of SRL monotherapy (Table [2](#Tab2){ref-type="table"}) by comparing sc SRL with sc ADA \[[@CR31], [@CR32]\]. At 24 weeks, ACR20/50/70 response rates and improvements in HAQ score, DAS28(ESR) remission, and CDAI remission were significantly greater with SRL than ADA monotherapy \[[@CR31]\].

Sirukumab Monotherapy {#Sec16}
---------------------

No publications compared SRK monotherapy with SRK + csDMARD combination therapy. Four publications from four different studies, predominantly in csDMARD-U/I patients, provided data on the efficacy of SRK monotherapy (Table [2](#Tab2){ref-type="table"}). One study in csDMARD-naïve patients comparing two doses of SRK monotherapy showed that more patients achieved ACR20/50/70 responses with 100 mg q2w SRK than with 50 mg q4w by 24 weeks, but there was no placebo or active comparator in this study \[[@CR54]\]. Two studies compared these same SRK doses with placebo \[[@CR55], [@CR56]\]. More patients achieved ACR20/50 responses, DAS28(CRP) remission, and improvements in HAQ score with SRK than with placebo at both 16 and 24 weeks, with the two SRK doses being generally comparable \[[@CR55], [@CR56]\]. One publication from the SIRROUND-H study compared sc SRK with sc ADA \[[@CR33]\]. ACR20/50 response rates were similar for SRK and ADA; however, patients receiving SRK (50 mg q4w and 100 mg q2w) had significantly better DAS28(ESR) change from baseline, and patients receiving 100 mg q2w SRK had significantly better DAS28(ESR) remission rates at 24 weeks than patients receiving ADA monotherapy \[[@CR33]\].

Tocilizumab Monotherapy {#Sec17}
-----------------------

Twenty publications from 14 RCTs, predominantly in csDMARD-U/I patients, provided data on the efficacy of TCZ monotherapy (Table [2](#Tab2){ref-type="table"}).

Six studies directly compared TCZ monotherapy with TCZ + csDMARD combination therapy \[[@CR57]--[@CR65]\]. In the FUNCTION study of MTX-naïve patients, a greater number of patients achieved ACR20/50/70 and DAS28(ESR) remission with TCZ + MTX combination therapy versus TCZ monotherapy over 1--2 years, and a greater proportion of patients receiving TCZ monotherapy achieved ACR20/50/70 and DAS28(ESR) remission versus MTX monotherapy (significance not reported) \[[@CR57]--[@CR60]\]. Five studies compared TCZ + MTX combination therapy with either TCZ monotherapy or TCZ plus placebo (effectively monotherapy) in csDMARD-U/I patients. The unblinded ACT-STAR study compared 8 mg/kg TCZ monotherapy with TCZ + csDMARD combination therapy (4 or 8 mg/kg). After 24 weeks, the ACR20/50/70 response rates were similar for TCZ monotherapy and both TCZ + csDMARD combination therapy doses \[[@CR61]\]. The SURPRISE study compared TCZ monotherapy with TCZ + MTX. DAS28(ESR) remission rates were higher with combination therapy than with TCZ monotherapy (*P* = 0.04), but differences between ACR20/50/70 response rates and CDAI and Simple Disease Activity Index (SDAI) remission rates between groups were not significant \[[@CR62]\]. The double-blind ACT-RAY study treated patients with either TCZ + placebo or TCZ + MTX for 24 weeks. DAS28(ESR) remission rates and ACR20/50/70 response rates were similar for TCZ + MTX and TCZ + placebo (differences were not significant) \[[@CR63]\]. The OPTIMISE study treated all patients with TCZ + MTX for 12 weeks and then randomized patients to treatment with either TCZ + MTX or TCZ + placebo, but analyzed them on the basis of anti-cyclic citrullinated peptide status rather than treatment group. DAS28 and CDAI changed significantly from baseline to week 12 (*P* \< 0.001), but did not change from week 12 to 24 \[[@CR64]\]. The final study treated all patients with TCZ + MTX for 16 weeks and then randomized patients to either continue TCZ + MTX or switch to TCZ + placebo with a follow-up at 28 weeks. DAS28(ESR) remission rates were similar for both groups at 28 weeks \[[@CR65]\].

The STREAM study was the only study to compare iv TCZ to placebo. The number of patients achieving ACR20/50/70 was greater with TCZ monotherapy than with placebo, and treatment discontinuation due to lack of efficacy was higher with placebo than with TCZ monotherapy over 3 months \[[@CR66]\].

The MUSASHI RCT (and open-label extension) compared the efficacy of iv TCZ versus sc TCZ in Japanese patients. At 24 weeks, more patients achieved ACR20/50/70 responses, DAS28(ESR) remission, and CDAI remission with iv TCZ monotherapy than with sc TCZ monotherapy \[[@CR67], [@CR68]\]. Another study in Japanese patients, focusing on patients with an inadequate response to q2w dosing, compared two different sc TCZ dosing frequencies. Change in DAS28(ESR) was significantly greater over 12 weeks with qw dosing than with q2w dosing \[[@CR69]\].

Four studies were of TCZ monotherapy versus a csDMARD. The TOMERA \[[@CR70]\] study of csDMARD-naïve patients, and the AMBITION study where 89% of patients were csDMARD-naïve \[[@CR30], [@CR60], [@CR71]\], compared TCZ with MTX. In the TOMERA study, more patients achieved DAS28(CRP), SDAI, ACR-EULAR Boolean-defined remission, and an SJC of 0 with TCZ than with MTX at 6 months \[DAS28(CRP) remission non-significant, all others *P* ≤ 0.01\]; after 6 months, all patients received MTX \[[@CR70]\]. The AMBITION study compared TCZ monotherapy with MTX in patients who had not previously failed MTX treatment. Significantly more patients achieved ACR20/50/70 responses with TCZ than MTX \[[@CR71]\], and a higher proportion of patients receiving TCZ achieved DAS28(ESR) remission compared with those receiving MTX, although this difference was non-significant \[[@CR60]\]. In addition, TCZ monotherapy was more effective than MTX in improving patient-reported outcomes (PROs) including CDAI and HAQ-disability index score \[[@CR30]\]. The SAMURAI \[[@CR72], [@CR73]\] and SATORI \[[@CR74]\] studies of TCZ monotherapy versus csDMARD were in csDMARD-U/I patients. In both studies, the numbers of patients achieving ACR20/50/70 responses were higher for TCZ monotherapy versus csDMARD \[[@CR72], [@CR74]\].

Finally, the ADACTA head-to-head study of TCZ monotherapy versus ADA monotherapy in csDMARD-U/I patients reported a significantly greater number of patients achieving ACR20/50/70 (all *P* \< 0.005), DAS28(ESR) remission (*P* \< 0.001), CDAI remission (*P* = 0.04), and good EULAR response (*P* \< 0.001) with TCZ monotherapy than with ADA monotherapy \[[@CR29]\]. In addition, improvements in PROs were greater with TCZ than ADA monotherapy for all parameters assessed \[[@CR30]\].

Tofacitinib Monotherapy {#Sec18}
-----------------------

No publications compared TOFA monotherapy with TOFA + csDMARD combination therapy. Fifteen publications comprising five RCTs provided data on the efficacy of TOFA monotherapy (Table [2](#Tab2){ref-type="table"}). The majority of studies were in csDMARD-U/I patients and compared TOFA monotherapy with placebo.

One phase 3 study in DMARD-U/I patients compared 5 and 10 mg bid TOFA with placebo, using a study design where patients were treated for 3 months, and then patients receiving placebo were blindly re-randomized to 5 or 10 mg bid TOFA for a further 3 months. At 3 months in the ORAL SOLO study \[[@CR75], [@CR76]\], ACR20/50/70 response rates were significantly higher at 3 months for both TOFA doses versus placebo \[all *P* \< 0.001 except ACR70 5 mg bid (*P* = 0.003)\] \[[@CR75]\]. The percentage of patients achieving DAS28(ESR) remission was numerically higher for both TOFA doses versus placebo but the between-group differences were not statistically significant \[[@CR75]\]. After the first 3 months of treatment, patients receiving TOFA monotherapy also reported statistically significant and clinically meaningful improvements in several PROs compared with patients receiving placebo \[[@CR76]\].

The two other studies of TOFA monotherapy versus placebo were phase 2 dose-ranging studies comparing a wider range of TOFA doses. The first study compared five doses of TOFA (1, 3, 5, 10, and 15 mg bid) with placebo. ACR20 response rates were statistically significantly higher with TOFA monotherapy than placebo at 12 weeks (*P* \< 0.05, all doses). ACR50/70 response rates and DAS28(ESR) remission rates were also significantly greater with TOFA (doses ≥ 5 mg bid) than placebo at 12 weeks (*P* \< 0.05) \[[@CR77], [@CR78]\]. The second study compared TOFA 5/15/30 mg bid with placebo. By 6 weeks, ACR20/50/70 response rates were significantly higher with TOFA monotherapy than placebo \[all *P* \< 0.001 except for ACR70, 5 mg bid (*P* \< 0.05)\], and the percentage of patients achieving a EULAR good response was higher for all TOFA doses than for placebo \[[@CR79]\].

One placebo-controlled trial of TOFA monotherapy also compared 1, 3, 5, 10, and 15 mg bid TOFA monotherapy and ADA (40 mg q2w) monotherapy with placebo. At 12 weeks, ACR20 response rates were significantly higher for 3--15 mg TOFA than for placebo (3 mg, *P* ≤ 0.05; 5/10/15 mg, *P* \< 0.001) and DAS28(ESR) remission was significantly higher for ≥ 10 mg TOFA than for placebo (*P* ≤ 0.05). ACR50/70 response rates were significantly higher in the TOFA dose groups compared with placebo at 12 weeks \[in those receiving ≥ 5 (ACR50) and ≥ 10 mg (ACR70) bid\] and 24 weeks \[in those receiving ≥ 3 (ACR50) and ≥ 5 mg (ACR70) bid\] \[[@CR27]\].

The ORAL START \[[@CR80]--[@CR88]\] study in MTX-naïve patients compared TOFA monotherapy (5 and 10 mg bid) with MTX monotherapy (10--20 mg/week). The number of patients achieving ACR20/50/70 (all *P* \< 0.0001) and DAS28(ESR) remission (5 mg, *P* \< 0.05; 10 mg, *P* \< 0.001) at 6 months was shown to be significantly greater with 5 mg and 10 mg TOFA than with MTX \[[@CR82]\]. At 104 weeks, ACR20/50/70 and DAS28(ESR) remission rates were still significantly higher with TOFA than MTX (*P* \< 0.05 for most outcomes) \[[@CR84]\]. Radiographic outcomes were also significantly improved with TOFA at 24 weeks compared with MTX (*P* \< 0.05) \[[@CR82]\]. In addition, two subset responder analyses showed that a greater proportion of patients achieved other clinical outcomes with TOFA, including SDAI and CDAI low disease activity and remission, than with MTX at 6 months \[[@CR80], [@CR81]\]. Greater improvements from baseline with TOFA versus MTX were observed for PROs including HAQ at 3, 6, 12, and 24 months (*P* \< 0.05 for the majority of outcomes assessed) \[[@CR85], [@CR86]\].

Discussion {#Sec19}
==========

The objective of this study was to evaluate the clinical evidence, published on or before April 11, 2017, regarding the efficacy of the bDMARDs ABA, ADA, CZP, ETN, SRK, SRL, TCZ, and the tsDMARDs TOFA and BARI as monotherapy for the treatment of RA. Comparisons of b/tsDMARDs with placebo or with a csDMARD consistently showed b/tsDMARDs to be efficacious treatments, regardless of whether patients were csDMARD-naïve or csDMARD-intolerant. However, better treatment outcomes were usually achieved when in combination with a csDMARD, and this was observed for all b/tsDMARDs assessed by this review. The benefits observed with the co-administration of a csDMARD such as MTX with a b/tsDMARD have been suggested to result from the effect of MTX to (1) reduce inflammation and radiographic progression, (2) increase the bioavailability of the bDMARD (for ADA and infliximab), and (3) attenuate anti-drug antibodies, all of which may also prolong treatment durability \[[@CR10]\]. However, MTX can have a pharmacokinetic interaction with bDMARDs; it has been shown that there is an increased risk of infections with MTX and ADA, CZP, infliximab, and golimumab combination therapy \[[@CR89]\] and therefore for some patients, monotherapy may be the preferred treatment option.

In clinical practice, patients receiving b/tsDMARD monotherapy for RA are either csDMARD-naïve or have previously failed treatment with csDMARD(s). We found that the amount of evidence for the efficacy of b/tsDMARD monotherapy differs for these two groups of patients.

For csDMARD-naïve patients with RA, there was no evidence to support the use of CZP or SRL as monotherapy. For ABA \[[@CR18]--[@CR22]\], BARI \[[@CR34], [@CR35]\], ETN \[[@CR49]\], SRK \[[@CR33]\], and TOFA \[[@CR80]--[@CR88]\], the efficacy of each treatment as monotherapy was supported by only a single study. For ABA, BARI, ETN, and TOFA, monotherapy was more efficacious than MTX. For SRK, monotherapy was shown to be more efficacious than ADA for some outcomes, but not others. For ADA \[[@CR24], [@CR33]\] and TCZ \[[@CR57]--[@CR60], [@CR70], [@CR71]\], the efficacy of each treatment as monotherapy was supported by two and three studies, respectively. ADA monotherapy efficacy was similar to MTX, while comparisons with SRK only showed superiority for some outcomes. TCZ monotherapy was more efficacious than MTX. TCZ + csDMARD combination therapy was more efficacious than TCZ monotherapy in this patient population \[[@CR57]--[@CR60]\].

For csDMARD-U/I patients with RA, most of the b/tsDMARDs assessed in this study were more efficacious in combination with MTX than as monotherapy. No studies in BARI were conducted in csDMARD-U/I patients. For ABA \[[@CR23]\] and SRL \[[@CR31], [@CR32]\], the efficacy of each treatment as monotherapy was supported by only a single study. ABA monotherapy was more efficacious than MTX and SRL monotherapy was more efficacious than ADA in this patient population. For CZP, monotherapy efficacy was supported by three studies \[[@CR36]--[@CR38]\] but was not shown to be as efficacious as combination therapy. For SRK \[[@CR33], [@CR54]--[@CR56]\] and TOFA \[[@CR27], [@CR75]--[@CR79]\], monotherapy efficacy was supported by four studies. SRK was more efficacious than placebo but comparisons with ADA only showed superiority for some outcomes. TOFA was more efficacious than placebo and ADA (although only one study had both TOFA and ADA treatment arms and this study was not designed to directly compare the two treatments). The largest number of studies in csDMARD-U/I patients were available for ADA, ETN, and TCZ. ADA monotherapy was consistently more efficacious than placebo, but no comparisons were made with MTX. ADA monotherapy was less efficacious than other b/tsDMARDs in head-to-head comparisons \[[@CR25]--[@CR33]\]. ETN and TCZ monotherapies were consistently more efficacious than placebo and csDMARDs. These two treatments also compared ETN and TCZ monotherapy with treatment in combination with csDMARDs. ETN combination therapy was more efficacious than ETN monotherapy \[[@CR42]--[@CR46]\]. For TCZ in csDMARD-U/I patients, TCZ monotherapy was not inferior to TCZ + csDMARD combination therapy \[[@CR61], [@CR64], [@CR65]\]. Previous SLRs of b/tsDMARD monotherapy in patients with an inadequate response to csDMARDs have also reported similar efficacy of TCZ and TCZ + MTX for ACR responses \[[@CR13]\] and PROs \[[@CR14]\].

Overall, the data reviewed in this SLR suggest that several b/tsDMARDs can be used as monotherapy, although several studies were in csDMARD-naïve patients, which is not generalizable to usual clinical practice. Better treatment outcomes were usually achieved when in combination with a csDMARD, so a key question for any clinician considering treating a patient with monotherapy rather than combination therapy is the efficacy of which treatment will diminish the least without concomitant csDMARDs. No head-to-head monotherapy versus combination therapy studies of TCZ \[[@CR57]--[@CR59], [@CR61], [@CR63], [@CR64]\], or the only study of BARI \[[@CR34]\], showed statistically significant differences in ACR20 responses between combination and monotherapy while both the JESMR \[[@CR42], [@CR43]\] and TEMPO \[[@CR44]--[@CR46]\] studies of ETN, the PREMIER study of ADA \[[@CR24]\], and the AVERT study of ABA \[[@CR18]\] all showed statistically significant differences in ACR20 responses between combination and monotherapy. The PREMIER study also showed significant differences in number of patients in DAS28(CRP) remission between combination and monotherapy, while the TEMPO and Combe et al. \[[@CR40], [@CR41]\] ETN studies showed significant differences in mean DAS28 score between combination and monotherapy. This could suggest that BARI and TCZ might be more efficacious as monotherapy than ABA, ADA, or ETN. However, more head-to-head studies of all these treatments are needed to further evaluate this, as the benefits of combination therapy over monotherapy were examined by at most three head-to-head studies for each treatment (with the exception of TCZ, where seven studies compared combination and monotherapy), and for SRL, SRK, and TOFA no such studies were identified.

This analysis had some limitations. No new information regarding in which order b/tsDMARDs should be used as monotherapy, or why one should be selected for use over others, is presented. Another limitation is the heterogeneity observed between study characteristics that are modifiers of the treatment effects, and heterogeneity resulting from inclusion of studies from several different countries. Previous analyses of bDMARD monotherapy have specifically excluded studies in exclusively non-Western populations \[[@CR13]\] but this did not. Non-Western populations, especially Japan, use lower and possibly suboptimal doses of MTX, limiting the differences between monotherapy and combination therapy. In addition, poor-quality studies were not excluded, although study quality was taken into account when interpreting treatment outcomes. Also, the durability of monotherapy versus combination treatments was not taken into account when evaluating treatment efficacy. Issues such as patient tolerability and acceptability are a reality with DMARDs but are not considered in RCTs. Differential retention may affect whether one drug is used over another in patients receiving monotherapy but this cannot be concluded from this SLR. Also, measures such as ACR20 which capture smaller improvements in disease activity may not differentiate between monotherapy versus combination therapy, but greater measures of improvements such as ACR70 or DAS/DAS28 remission may do so. Safety and cost may also be important in choosing one treatment over another in patients using monotherapy. Finally, this analysis did not address differences in safety outcomes for the studies included, meaning that only the benefit of these treatments, and not the risk/benefit, could be assessed.

The conclusions that can be drawn from this analysis are also limited by the types of studies identified by the search parameters. There were very few head-to-head studies of different b/tsDMARDs as monotherapy. Dosing schedules varied and most studies did not compare multiple doses of the b/tsDMARDs being evaluated, meaning that the efficacy of higher doses of these monotherapy treatments could not be assessed. The retention on a specific drug and real-world effectiveness, tolerability, and safety were also not within the scope of this study.

Conclusions {#Sec20}
===========

The findings of this SLR highlight the benefits of bDMARDs in combination with csDMARDS, and in some instances also in monotherapy. In csDMARD-naïve patients, b/tsDMARD monotherapy was generally more efficacious than csDMARD monotherapy, but b/tsDMARD + csDMARD combination therapy was more efficacious than b/tsDMARD monotherapy. In csDMARD-U/I patients, most of the b/tsDMARDs assessed in this study were more efficacious than csDMARDs, but were also more efficacious as combination therapy with a csDMARD than as monotherapy. However, in this patient population, TCZ monotherapy was not inferior to TCZ + csDMARD combination therapy. This SLR confirms a favorable efficacy profile of these therapies and emphasizes areas in need of further investigation. There is a need for longer-term head-to-head trials to fully establish positioning of these interventions in the treatment algorithm for RA.
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